Suppr超能文献

相似文献

1
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Mol Oncol. 2008 Apr;1(4):395-405. doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28.
2
GAB2 amplifications refine molecular classification of melanoma.
Clin Cancer Res. 2009 Jul 1;15(13):4288-91. doi: 10.1158/1078-0432.CCR-09-0280. Epub 2009 Jun 9.
3
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447.
4
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
J Clin Pathol. 2005 Jun;58(6):640-4. doi: 10.1136/jcp.2004.022509.
5
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Br J Dermatol. 2011 Apr;164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x. Epub 2011 Mar 21.
6
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7. doi: 10.1158/1055-9965.EPI-06-1038.
7
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
J Invest Dermatol. 2006 Jan;126(1):154-60. doi: 10.1038/sj.jid.5700026.
9
Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Br J Dermatol. 2014 Oct;171(4):754-9. doi: 10.1111/bjd.13069. Epub 2014 Sep 10.

引用本文的文献

2
Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma.
Cancers (Basel). 2024 Jan 15;16(2):365. doi: 10.3390/cancers16020365.
3
Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.
Dermatopathology (Basel). 2024 Jan 18;11(1):26-51. doi: 10.3390/dermatopathology11010005.
4
The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides.
Front Oncol. 2023 Oct 26;13:1261090. doi: 10.3389/fonc.2023.1261090. eCollection 2023.
5
New Treatment Horizons in Uveal and Cutaneous Melanoma.
Life (Basel). 2023 Jul 31;13(8):1666. doi: 10.3390/life13081666.
6
C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma.
Heliyon. 2023 Aug 6;9(8):e18953. doi: 10.1016/j.heliyon.2023.e18953. eCollection 2023 Aug.
7
Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Oncol Lett. 2023 Jul 20;26(3):382. doi: 10.3892/ol.2023.13968. eCollection 2023 Sep.

本文引用的文献

2
Differential oncogenic potential of activated RAS isoforms in melanocytes.
Oncogene. 2007 Jul 5;26(31):4563-70. doi: 10.1038/sj.onc.1210239. Epub 2007 Feb 5.
4
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.
Cancer Res. 2007 Jan 1;67(1):122-9. doi: 10.1158/0008-5472.CAN-06-1880.
7
Somatic activation of KIT in distinct subtypes of melanoma.
J Clin Oncol. 2006 Sep 10;24(26):4340-6. doi: 10.1200/JCO.2006.06.2984. Epub 2006 Aug 14.
8
Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?
J Invest Dermatol. 2006 Aug;126(8):1693-6. doi: 10.1038/sj.jid.5700458.
9
BRAF and NRAS mutations in melanoma and melanocytic nevi.
Melanoma Res. 2006 Aug;16(4):267-73. doi: 10.1097/01.cmr.0000222600.73179.f3.
10
MC1R germline variants confer risk for BRAF-mutant melanoma.
Science. 2006 Jul 28;313(5786):521-2. doi: 10.1126/science.1127515. Epub 2006 Jun 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验